WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
China to build an investorsAustralian freshwater crayfish bring fresh vitality to rural XinjiangTaiwan students can apply for mainland universities from March 1Hayao Miyazaki's animated fantasy leads Chinese box officeSudan: Aid groups warn of mass death from hungerHarvest of renowned Longjing tea begins in east ChinaTrain carries 261 vehicles from China's Lanzhou to AlmatyPupils welcome new semester with lively activities in N China's HohhotTeyana Taylor shows off her toned figure in denimHKSAR LegCo unanimously passes national security bill
3.3006s , 6498.8828125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Universal Unfoldings news portal